P2‐320: Cost‐effectiveness of Memantine Extended Release for Treatment of Moderate‐to‐severe Alzheimer's Disease in the United States

Thibault, Catherine Saint-Laurent; Stillman, Ipek Özer; Chen, Stephanie; Getsios, Denis; Proskorovsky, Irina; Hernández, Luis; Dixit, Shailja

doi:10.1016/j.jalz.2014.05.999

Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.

Alzheimer's & Dementia

2014

DOI: 10.1016/j.jalz.2014.05.999

|View full text |Cite

P2‐320: Cost‐effectiveness of Memantine Extended Release for Treatment of Moderate‐to‐severe Alzheimer's Disease in the United States

Catherine Saint-Laurent Thibault

Ipek Özer Stillman

Stephanie Chen³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

2019

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Memantine for dementia

McShane

Westby

Roberts

et al. 2019

Cochrane Database of Systematic Reviews

232

192

View full text Add to dashboard Cite

Memantine for dementia

McShane

Westby

Roberts

et al. 2019

Cochrane Database of Systematic Reviews

232

192

View full text Add to dashboard Cite

Memantine Extended Release (28 mg Once Daily): A Review of Its Use in Alzheimer’s Disease

Plosker

2015

Drugs

View full text Add to dashboard Cite

Memantine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that is a well-established treatment option for moderate to severe dementia of the Alzheimer's type, either alone or in combination with cholinesterase inhibitors. The immediate-release (IR) formulations of memantine (tablets and oral solution) have been available in numerous countries, including the USA, for more than a decade and are administered orally twice daily at a maximum recommended total daily dosage of 20 mg/day. The memantine extended-release (ER) (Namenda XR(®)) 28 mg once-daily capsule formulation was approved in the USA in 2010 and became available more recently. The potential advantages of memantine ER over the IR formulation include a more convenient dosage regimen and lower pill burden that may improve adherence to therapy; also, memantine ER capsules may be opened and the contents sprinkled on applesauce for patients who have difficulty swallowing. Memantine ER provides a higher total daily dosage than the recommended memantine IR regimen and pharmacokinetic data indicate greater exposure with the ER formulation, but the clinical implications of this are unclear, as the two formulations have not been assessed in a comparative clinical trial. The efficacy of memantine ER 28 mg once daily was demonstrated in a large, multinational, phase III trial, which showed that the addition of memantine ER to ongoing oral cholinesterase inhibitors improved key outcomes compared with cholinesterase inhibitor monotherapy, including measures of cognition and global status, which were the co-primary endpoints of the study. The most common adverse events were headache, diarrhoea and dizziness.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

P2‐320: Cost‐effectiveness of Memantine Extended Release for Treatment of Moderate‐to‐severe Alzheimer's Disease in the United States

Cited by 2 publications

References 0 publications

Memantine for dementia

Memantine for dementia

Memantine Extended Release (28 mg Once Daily): A Review of Its Use in Alzheimer’s Disease

Contact Info

Product

Resources

About